Results 61 to 70 of about 351,966 (398)
Adipocytes cause leukemia cell resistance to daunorubicin via oxidative stress response. [PDF]
, 2016 Adipocytes promote cancer progression and impair treatment, and have been shown to protect acute lymphoblastic leukemia (ALL) cells from chemotherapies. Here we investigate whether this protection is mediated by changes in oxidative stress.
Behan, James W +6 more
core +1 more source
Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting
Molecular Oncology, EarlyView.CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia +9 more
wiley +1 more source
Acute Lymphoblastic Leukemia, Classification, Clinical features and Diagnosis
Diyala Journal of Medicine, 2020 Background: Leukemias are classified as lymphoid or myeloid, dependent on the type of stem cell that is affected. In addition, leukemia is classified as chronic or acute.
Fatimah Kadhim Ibrahim AL- Mahdawi +1 more
doaj +2 more sources
Preserved cellular immunity in smoldering acute leukemia [PDF]
, 1976 "Smoldering acute leukemia", a variant of acute myelogenous leukemia, has been recognized with frequent incidence in recent years. This is chracterized by benign clinical course, poor physical findings, leukopenia and mild anemia in the ...
Toki, Hironobu
core +1 more source
Peroxidasin enables melanoma immune escape by inhibiting natural killer cell cytotoxicity
Molecular Oncology, EarlyView.Peroxidasin (PXDN) is secreted by melanoma cells and binds the NK cell receptor NKG2D, thereby suppressing NK cell activation and cytotoxicity. PXDN depletion restores NKG2D signaling and enables effective NK cell–mediated melanoma killing. These findings identify PXDN as a previously unrecognized immune evasion factor and a potential target to improve
Hsu‐Min Sung +17 more
wiley +1 more source
Wnt5a causes ROR1 to complex and activate cortactin to enhance migration of chronic lymphocytic leukemia cells. [PDF]
, 2019 Chronic lymphocytic leukemia cells (CLL) migrate between the blood and lymphoid tissues in response to chemokines. Such migration requires structured cytoskeletal-actin polymerization, which may involve the protein cortactin. We discovered that treatment
Hasan, Md Kamrul +4 more
core +1 more source
The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity
Molecular Oncology, EarlyView.Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli +7 more
wiley +1 more source
Frontiers in Oncology, 2021 Despite recent advancements in the treatment of hematologic malignancies and the emergence of newer and more sophisticated therapeutic approaches such as immunotherapy, long-term overall survival remains unsatisfactory.
Mojdeh Soltani +5 more
doaj +1 more source
Faktor-Faktor Berhubungan Dengan Kualitas Hidup Anak Leukemia Limfositik Akut Yang Menjalani Kemoterapi [PDF]
, 2016 Acute lymphocytic leukemia is a type of leukemia that is most prevalent among children which is around 75-80%. The progress of chemotherapy for acute lymphocytic leukemia has increased the survival rate for this cancer. However, the length of life of the
Agustini, N. (Nur) +2 more
core +2 more sources
FEBS Open Bio, EarlyView.Representation of the suggested mode of action of lactoferrin (Lf) in nonsmall cell lung cancer (NSCLC) A549 cells. Lf induces activation of caspase‐3 by activating p53 and AChE leading to decreased ACh concentrations. In turn, ACh signaling leads to activation of VEGF and AKT and blocking of caspase‐3.
Stuti Goel +9 more
wiley +1 more source